A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Nat Chem Biol. 2009; 5: 749-757
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Nat Med. 2015; 21: 27-36
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Sci Transl Med. 2013; 5209ra151
The new biology and pharmacology of glucagon.
Physiol Rev. 2017; 97: 721-766
Anti-obesity drug discovery: advances and challenges.
Nat Rev Drug Discov. 2022; 21: 201-223
Tirzepatide once weekly for the treatment of obesity.
N Engl J Med. 2022; 387: 205-216
Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial.
JAMA. 2022; 327: 534-545
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet. 2021; 398: 1811-1824
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.
N Engl J Med. 2021; 385: 503-515
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
Lancet. 2021; 398: 583-598
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
Lancet. 2021; 398: 143-155
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept.
Cell Metab. 2022; 34: 1234-1247
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice.
Mol Metab. 2022; 63101533
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes.
Diabetes Obes Metab. 2011; 13: 426-433
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
Lancet. 2022; 400: 1869-1881